FDA Semaglutide Shortage Resolved: What It Means for Compounded GLP-1s in 2026
The FDA declared the semaglutide shortage over in February 2025. Tirzepatide was resolved months earlier. Here's exactly what happened, what's still legal, and what the April 2026 crackdown means for patients.
If you've been searching for clarity on whether compounded semaglutide is still available in 2026, you're not alone. The regulatory landscape has changed significantly since early 2025, and the news cycle has made it harder to separate fact from speculation.
Here's the timeline, documented with primary sources.
The Timeline: How We Got Here
| Date | Event |
|---|---|
| 2022 | FDA places semaglutide and tirzepatide on the drug shortage list due to surging demand. This opens legal pathway for 503A and 503B compounding pharmacies to produce copies. |
| Oct 2024 | FDA resolves the tirzepatide shortage. Issues guidance that 503B facilities must stop compounding. Legal challenges filed immediately. |
| Dec 2024 | FDA reaffirms tirzepatide determination in declaratory order. Sets enforcement discretion deadlines. |
| Feb 21, 2025 | FDA resolves the semaglutide shortage for all injectable presentations (Ozempic/Wegovy). Sets 503A deadline at April 22, 2025 and 503B deadline at May 22, 2025. |
| Apr 24, 2025 | Court denies preliminary injunction in OFA v. FDA regarding semaglutide. 503A enforcement discretion period ends. |
| May 22, 2025 | 503B enforcement discretion deadline passes. Large-scale outsourcing facilities can no longer compound "essentially a copy" semaglutide products. |
| Sep 2025 | FDA issues 50+ warning letters to GLP-1 compounders and telehealth companies for misleading marketing claims. |
| Mar 3, 2026 | FDA issues 30 additional warning letters to telehealth companies for false claims about compounded GLP-1 products. |
| Apr 30, 2026 | FDA proposes removing semaglutide, tirzepatide, and liraglutide from the 503B bulk compounding list entirely. Public comment period open through June 29, 2026. |
Is Compounded Semaglutide Still Legal?
The short answer: it depends on the type of pharmacy and the circumstances.
503A pharmacies (patient-specific compounding): State-licensed compounding pharmacies operating under Section 503A of the FD&C Act can still compound semaglutide — and tirzepatide — with a valid patient-specific prescription. This pathway operates under a different legal framework than the shortage list. It requires a documented clinical need (such as a different dose, route, or removal of an allergen) and the product cannot be "essentially a copy" of the commercially available drug.
503B outsourcing facilities (large-scale compounding): The shortage-based pathway is closed. Courts denied injunctions, enforcement deadlines passed, and the FDA is now proposing to permanently remove these drugs from the 503B bulk compounding list. A public comment period is open through June 29, 2026, but the direction is clear.
The FDA's proposed rule would permanently bar 503B outsourcing facilities from bulk compounding semaglutide, tirzepatide, and liraglutide — even if a new shortage were declared. This is a proposal, not yet final. 503A patient-specific compounding would remain unaffected by this rule.
What Are the Options Now?
For patients currently on compounded GLP-1 medications or considering starting treatment, the landscape has narrowed but not disappeared. Here's what's available in May 2026:
Brand-name medications with manufacturer savings programs: Oral Wegovy starts at $149/month through NovoCare. Foundayo (orforglipron), newly FDA-approved in April 2026, also starts at $149/month via LillyDirect. Zepbound runs $399–549/month through LillyDirect.
Telehealth providers with 503A pharmacy partnerships: Several licensed telehealth platforms continue operating through compliant 503A compounding pharmacies with valid patient-specific prescriptions. These providers typically bundle the medical consultation, prescription, and medication into one fee.
Insurance coverage: The BALANCE Model announced by CMS in December 2025 is expected to expand Medicare coverage for GLP-1 medications for obesity, with capped copays around $50/month. Medicaid rollout is expected as early as mid-2026.
Verified Providers Accepting New Patients
GLP-1 treatment programs with streamlined intake and licensed clinical oversight.
Starting from $199/mo
⚠️ Compounded medications are not FDA-approved. Paid link.
Direct intake GLP-1 programs with personalized treatment plans and ongoing support.
Semaglutide from $239/mo
⚠️ Compounded medications are not FDA-approved. Paid link.
Affordable GLP-1 programs with semaglutide and tirzepatide options. Multi-month plan pricing available.
Semaglutide from $146/mo (6-mo plan)
⚠️ Compounded medications are not FDA-approved. Paid link.
Affordable direct care platform for FDA-approved brand-name GLP-1 consultations with licensed clinicians.
Consultations from $99
Paid link.
The era of mass-produced compounded GLP-1s through 503B outsourcing facilities is effectively over. But 503A patient-specific compounding remains legal, brand-name options have become significantly more affordable, and new oral alternatives (Wegovy pill, Foundayo) have lowered the entry point to $149/month. The regulatory picture is still evolving — the public comment period on the FDA's proposed rule closes June 29, 2026.
Sources
- FDA. Clarification on compounding policies as GLP-1 supply stabilizes. Updated April 2026. fda.gov
- Burr & Forman LLP. The FDA Removes Semaglutide from the Drug Shortage List. February 2025. burr.com
- McDermott Will & Emery. Semaglutide Shortage Resolved. March 2025. mwe.com
- Pharmacy Times. FDA Moves to Permanently Close the Door on Compounded GLP-1s. May 2026. pharmacytimes.com
- Wilson Sonsini. FDA Sends Warning Letters to More Than 50 GLP-1 Compounders. September 2025. wsgr.com
- Fierce Pharma. FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters. March 2026. fiercepharma.com
Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, regulatory analysis, or provider selection.